Marex Group’s AbbVie ABBV Stock Holding History

Marex Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.2M	Buy	+300,000	New	+$66.5M	0.41%	69

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marex Group's ABBV Position: Q1 2026 in Review

Marex Group increased its AbbVie (ABBV) stake by 24,116% in Q1 2026, buying an estimated $68.3M and bringing the position to 308,994 shares worth $67.2M. The position accounts for 0.42% of the portfolio, ranked #67.

Marex Group first reported a position in ABBV in Q4 2022 and has held it in 12 quarters since. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Marex Group held 308,994 shares of AbbVie worth $67.2M as of Q1 2026.
Marex Group bought 307,718 AbbVie shares in Q1 2026, an estimated $68.3M.
AbbVie made up 0.42% of Marex Group's portfolio in Q1 2026, its #67 holding.
Marex Group first reported a position in AbbVie in Q4 2022 and has held it in 12 quarters since.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.